Clinical response to MEL100 and MP in patients aged 65 to 70
. | MEL 100, no. (%) . | MP, no. (%) . | P . |
|---|---|---|---|
| No. | 44 (100) | 36 (100) | NA |
| Near complete remission | 11 (25) | 3 (8) | .05 |
| Partial remission | |||
| 75% to 99% reduction | 10 (22) | 3 (8) | .09 |
| 50% to 74% reduction | 9 (20) | 12 (33) | — |
| No response | 12 (27) | 13 (36) | — |
| Progressive disease | 2 (5) | 5 (14) | — |
| Early deaths | 3 (7) | 1 (3) | .29 |
. | MEL 100, no. (%) . | MP, no. (%) . | P . |
|---|---|---|---|
| No. | 44 (100) | 36 (100) | NA |
| Near complete remission | 11 (25) | 3 (8) | .05 |
| Partial remission | |||
| 75% to 99% reduction | 10 (22) | 3 (8) | .09 |
| 50% to 74% reduction | 9 (20) | 12 (33) | — |
| No response | 12 (27) | 13 (36) | — |
| Progressive disease | 2 (5) | 5 (14) | — |
| Early deaths | 3 (7) | 1 (3) | .29 |
NA indicates not applicable; —, not available.